Notícias Vanda Pharmaceuticals Inc - VNDA | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Vanda Pharmaceuticals Inc (VNDA)
Vanda Pharmaceuticals Inc (VNDA) Notícias

Vanda Pharmaceuticals Inc (VNDA)

4,56

0,03

( 0,66% )

Atualizado: 15:04:53

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Form 8-K - Current report

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results

Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024

Form 8-K - Current report

Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.

Form 8-K - Current report

Form 8-K - Current report

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Vanda Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições